Table 3.
The PASI score before the treatment (a baseline visit), after a 3-month therapy (a control visit) as well as PASI reduction in psoriasis patients treated with different therapies depending on the presence of comorbidities, BMI score and smoking status therapies depending on the presence of comorbidities, BMI score and smoking status.
| PASI Score before the Treatment (a Baseline Visit) | ||||||
|---|---|---|---|---|---|---|
| Analyzed factor, Me (Min-Max) | All appled therapies (n = 184) |
Methotrexate (n = 79) |
Cyclosporine (n = 42) |
Retinoids (n = 43) |
Biological Agents (n = 20) |
|
| Hypertension | Yes (n-62) |
18.4 (13.8–27) |
27.4 (22.3–34.6) |
21.4 (14–22.4) |
14.9 (13.8–21.2) |
25.2 (-) |
| No (n-122) |
14.2 (11.2–18.6) |
15.2 (13.6–18) |
14.2 (12.6–16.6) |
12.8 (10.8–14.2) |
28.1 (22.4–29.7) |
|
| p | <0.001 | <0.001 | 0.130 | 0.006 | 0.614 | |
| Diabetes | Yes (n-40) |
22.1 (14.4–28.6) |
30.6 (27–36.2) |
21.5 (16.8–24) |
21.3 (17.2–23.4) |
- |
| No (n-144) |
14.2 (11.2–18.8) |
16.8 (14.2–21.3) |
13.8 (12.2–14.4) |
13.4 (11.1–14.5) |
- | |
| p | <0.001 | <0.001 | <0.001 | <0.001 | - | |
| Lipid disorders | Yes n-(60) |
20.4 (14.1–27.7) |
27.5 (20.8–35) |
16.7 (14–22) |
- | 26.0 (-) |
| No (n-124) |
14.2 (11–17.9) |
16.0 (14–17.9) |
13.7 (11.8–17.2) |
- | 28.1 (22.4–29.7) |
|
| p | <0.001 | <0.001 | 0.004 | - | 0.753 | |
| BMI (kg/m2) | ≥25 (n-92) |
20.8 (14–27) |
26.7 (18.4–31.6) |
21.5 (17.3–24) |
15.0 (12.8–21.2) |
27.6 (22.4–29.7) |
| <25 (n-92) |
13.8 (11–15) |
15.0 (13.7–17.7) |
13.7 (12.2–14.4) |
13.2 (10.8–14.2) |
25.8 (23–27) |
|
| p | <0.001 | <0.001 | <0.001 | 0.005 | 0.706 | |
| Smoking status | Smoker (n-65) |
19.3 (13.8–26.7) |
26.4 (18.4–33.8) |
16.4 (13.5–21.5) |
16.8 (14.2–21.4) |
28.4 (23.4–31.1) |
| Non-smoker (n-119) |
14.2 (10.8–18.4) |
16.4 (14.3–25.3) |
14.2 (12.5–16.1) |
12.8 (10.8–14.2) |
26.8 (23.4–29.6) |
|
| p | <0.001 | <0.001 | 0.208 | <0.001 | 0.827 | |
| PASI Score after a 3-Month Therapy (a control Visit) | ||||||
| Analyzed factor, Me (Min-Max) |
All Appled Therapies
(n = 184) |
Methotrexate
(n = 79) |
Cyclosporine
(n = 42) |
Retinoids
(n = 43) |
Biological Agents
(n = 20) |
|
| Hypertension | Yes (n-62) |
10.0 (6.9–15.2) |
13.4 (9.2–19.4) |
10.8 (3.5–14.2) |
7.9 (6.8–11.2) |
5.8 (-) |
| No (n-122) |
4.8 (3.2–6.6) |
4.2 (3.2–6) |
4.4 (2.3–6.3) |
5.8 (3.8–7.9) |
6.2 (4.7–8.2) |
|
| p | <0.001 | <0.001 | 0.095 | 0.008 | 0.614 | |
| Diabetes | Yes (n-40) |
11.2 (7.4–16) |
16.0 (13.4–23) |
8.9 (6.3–11.3) |
13.2 (10.6–16.6) |
- |
| No (n-144) |
5.2 (3.4–7.2) |
4.8 (3.4–8.4) |
3.2 (1.6–5.2) |
6.4 (4.7–8.2) |
- | |
| p | <0.001 | <0.001 | <0.001 | 0.002 | - | |
| Lipid disorders | Yes (n-60) |
10.0 (5.1–15) |
14.3 (9–20) |
5.5 (3.6–9.9) |
- | 5.8 (-) |
| No (n-124) |
5.2 (3.4–7.4) |
4.4 (3.4–6.1) |
3.2 (1.6–5.6) |
- | 6.2 (4.7–8.2) |
|
| p | <0.001 | <0.001 | 0.023 | - | 0.706 | |
| BMI (kg/m2) | ≥25 (n-92) |
8.2 (5.8–13.4) |
11.6 (7.3–19.6) |
9.9 (6.6–11.3) |
7.9 (6.4–15.2) |
6.4 (5.2–8.2) |
| <25 (n-92) |
4.4 (3.2–6.2) |
4.2 (3.3–5.7) |
3.2 (1.6–5.2) |
6.2 (3.7–7.9) |
4.1 (2.4–5.8) |
|
| p | <0.001 | <0.001 | <0.001 | 0.016 | 0.208 | |
| Smoking status | Smoker (n-65) |
9.8 (6.3–15) |
13.2 (7–19) |
6.6 (5.3–11.1) |
9.7 (7–16.6) |
6.5 (5.2–8.5) |
| Non-smoker (n-119) |
4.8 (3.2–7.2) |
4.2 (3.4–9) |
3.4 (1.95–5.65) |
6.2 (3.8–7.7) |
5.8 (4.8–7.9) |
|
| p | <0.001 | <0.001 | 0.009 | 0.002 | 0.600 | |
| PASI Reduction from Baseline | ||||||
| Analyzed factor, Me (Min-Max) |
All Appled Therapies
(n = 184) |
Methotrexate
(n = 79) |
Cyclosporine
(n = 42) |
Retinoids
(n = 43) |
Biological Agents
(n = 20) |
|
| Hypertension | Yes (n-62) |
8.4 (4–12.4) |
12.4 (11–15.2) |
9.8 (8.2–10.7) |
6.1 (4.8–8.2) |
19.5 (-) |
| No (n-122) |
9.8 (7–13) |
11.1 (9–13) |
10.4 (9.2–11.4) |
7.0 (5.2–8.2) |
20.8 (17.7–22.3) |
|
| p | 0.079 | 0.025 | 0.268 | 0.546 | 0.674 | |
| Diabetes | Yes (n-40) |
10.3 (4.8–12) |
12.0 (11–15.6) |
10.9 (9.3–12.8) |
6.8 (4.8–8.2) |
- |
| No (n-144) |
9.4 (6–13) |
11.6 (9.3–13.2) |
9.9 (9.2–11.2) |
6.4 (5.2–8.2) |
- | |
| p | 0.518 | 0.255 | 0.277 | 0.972 | - | |
| Lipid disorders | Yes (n-60) |
11.0 (7.3–13) |
12.1 (11–15) |
10.8 (10.1–11.4) |
- | 20.2 (-) |
| No (n-124) |
8.6 (5.4–12.1) |
11.2 (9–13.5) |
9.3 (8.2–11) |
- | 20.1 (17.7–22.2) |
|
| p | 0.053 | 0.182 | 0.023 | - | 0.974 | |
| BMI (kg/m2) | ≥25 (n-92) |
10.6 (4.9–14.1) |
11.6 (10.5–13.6) |
11.0 (10.5–12.8) |
6.4 (5.6–7.8) |
19.9 (17.7–22.3) |
| <25 (n-92) |
9.2 (6.4–11.4) |
11.6 (9–13.5) |
9.8 (9.2–11) |
6.8 (4.8–8.3) |
21.7 (21.4–22) |
|
| p | 0.206 | 0.629 | 0.043 | 0.854 | 0.516 | |
| Smoking status | Smoker (n-65) |
8.4 (4.8–12.1) |
11.2 (9–13.2) |
8.2 (8.2–10.8) |
6.0 (4.8–7.8) |
20.2 (15.9–22.4) |
| Non-smoker (n-119) |
10.0 (6–13) |
12.0 (10.3–13.9) |
10.4 (9.4–11.4) |
6.8 (5.4–8.3) |
20.0 (18.2–22.2) |
|
| p | 0.285 | 0.356 | 0.045 | 0.476 | 0.800 | |